AGA Center for Diagnostics & Therapeutics

The mission of the AGA Center for Diagnostics and Therapeutics is to support the development of therapies and diagnostic tests that will enhance human health and improve the lives of patients with digestive disorders.
 
Drug development is a complex, time-consuming and expensive process requiring the cooperation of various stakeholders. The AGA Center for Diagnostics and Therapeutics was created to provide objective, independent guidance to companies, regulators, investors and health-care professionals on the development of new therapies and diagnostics tests for digestive disorders.
 

Message from center chair

Colin W. Howden, MD, AGAF, chair of the center, shares background on how the center came to be and what you can expect from the center in 2016.

 

meeting recap

AGA Drug Development Conference

The center's first annual AGA Drug Development Conference focused on the challenges in treating upper GI tract disorders, including GERD, eosinophilic esophagitis, gastroparesis and functional dyspepsia

coming soon

Stay tuned for white papers from the center, as well as information on center-sponsored sessions planned for Digestive Disease Week® 2017. 

 

work with the center

The AGA Center for Diagnostics and Therapeutics is available to consult with pharmaceutical, biotech and diagnostics companies on the challenges they may face as they try to bring new drugs, biologics and diagnostics to market. The center is also interested in working with investigators developing new medicines or diagnostic tests for digestive disorders who may require guidance from thought leaders in the field. 

Scientific Advisory Board

The core of the center is a 12-person steering committee; members represent GI practice and research, large and small biopharmaceutical companies, and FDA.

This group reports to the AGA Institute Governing Board and will interact directly with FDA as necessary.

 

Colin W. Howden, MD, AGAF

Colin W. Howden, MD, AGAF, chair

Chief of Gastroenterology, University of Tennessee Health Science Center, Memphis, TN

J. SUmner Bell, III, MD, AGAF

J. Summer Bell III, MD, AGAF

Gastroenterology Ltd., Virginia Beach, VA

Donna Griebel, MD

Donna Griebel, MD*

Supervisory Medical Officer, FDA Center for Drug Evaluation and Research, Silver Spring, MD

M. Scott Harris, MD, AGAF

M. Scott Harris, MD, AGAF

Avaxia Biologics and Georgetown University, Washington, DC

Jessica Lee, MD

Jessica Lee, MD*

Medical Officer, Team Leader, FDA Center for Drug Evaluation and Research, Silver Spring, MD

Loren Laine, MD, AGAF

Loren Laine, MD, AGAF

Professor of Medicine, Yale University School of Medicine, Fairfield, CT

Andrew Mulberg, MD

Andrew Mulberg, MD*

Supervisory Medical Officer, FDA Center for Drug Evaluation and Research, Silver Spring, MD

William J. Sandborn, MD, AGAF

William J. Sandborn MD, AGAF

Chief, Gastroenterology Division; Director, UCSD IBD Center, University of California, San Diego, CA

Debra G. Silberg, MD, PhD

Debra G. Silberg, MD, PhD

Senior Director, Clinical Development, Shire Pharmaceuticals, Wayne, PA

Stephan R. Targan, MD, AGAF

Stephan R. Targan, MD, AGAF

Director, F. Widjaja Foundation, Inflammatory Bowel and Immunology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA

Nimish B. Vakil, MD, AGAF

Nimish B. Vakil, MD, AGAF

Clinical Professor of Medicine, University of Wisconsin Medical School, Summit, WI

Teresa L. Wright, MD, AGAF

Teresa L. Wright, MD, AGAF

Product Development Immunology and Infectious Disease, Genentech, San Francisco, CA

AGA Staff Contact: Alison Kim

*Denotes non-voting member.